LLY spotlight — 2026-10-01
Eli Lilly & Co (LLY) is down 2.33% from the prior close, marking a notable divergence in its performance over different time horizons: it’s up 59.27% over the past year but has seen a decline of -2.91% over the last three months. This…
Key figures
Data as of Oct 1, 2026- LLY last close
- $1,157.08
- LLY change vs prior close
- -2.33%
- LLY trailing P/E
- 39.51
- LLY market cap
- $1.06T
Eli Lilly & Co (LLY) is down 2.33% from the prior close¹, marking a notable divergence in its performance over different time horizons: it’s up 59.27% over the past year but has seen a decline of -2.91% over the last three months²˒³. This mixed picture is further complicated by recent news sentiment, which skews overwhelmingly positive with 10 positive articles and no negative ones⁴.
LLY closed at $1157.08 on Wednesday⁵, within the higher range of its 52-week trading band (76.1%) but well below its high point of $1292.65 set over the past year⁶˒⁷. The company’s P/E ratio stands at 39.51, and it has a market cap of approximately $1.06T⁸˒⁹.
Recent coverage highlights promising developments in Lilly's new weight loss drug, with reports indicating significant weight loss among patients. Despite this positive news, the stock’s three-month performance suggests caution from investors or other external factors at play.
Educational tool. Not investment advice. This article was produced with automated assistance and reviewed before publishing.